PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)


Volume 2 Issue 1

Desultory and Glib-Adrenocortical Carcinoma

Anubha Bajaj*

June 09, 2023


     Adrenocortical carcinoma is an exceptionally discerned, malignant, endocrine, epithelial tumour emerging from adrenal cortical cells. The heterogeneous neoplasm may be engendered due to overexpression of IGF2 and is associated with significant mortality. Majority of neoplasms appear as sporadic lesions although may demonstrate diverse syndromic settings. Prognostic outcomes are contingent to age of incriminated subject, clinical representation, tumour stage, precise histological variant and molecular or genomic characteristics of the neoplasm.

     Additionally designated as adrenal cortical carcinoma (ACC), conventional subtype of adrenocortical carcinoma, adrenal cortical adenocarcinoma or malignant adrenal cortical tumour, the neoplasm configures around ~6.8% of primary adrenal neoplasms. Median age of disease occurrence is ~55 years although no age of disease emergence is exempt. A bimodal distribution of disease is encountered with peak occurrence within first decade and fifth decade. Caucasians are commonly implicated. A female preponderance is observed with male to female proportion of 1:1.5 - 2.5. Adrenocortical carcinoma is predominantly sporadic although ~10% instances arise within syndromic settings (1,2).


  1. Jing Y., et al. “Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population: A Cross-Sectional Study”. Ann Intern Med 175.10 (2022): 1383-1391.
  2. Gambella A, Volante M and Papotti M. “Histopathologic Features of Adrenal Cortical Carcinoma”. Adv Anat Pathol 30.1 (2023): 34-46.
  3. Torti JF and Correa R. Adrenal Cancer. Stat Pearls International 2022, Treasure Island, Florida.
  4. Mete O., et al. “Overview of the 2022 WHO Classification of Adrenal Cortical Tumors”. Endocr Pathol 33.1 (2022): 155-196.
  5. Arnon J., et al. “Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience”. J Endocr Soc 6.9 (2022): bvac112.
  6. Image 1 Courtesy:
  7. Image 2 Courtesy: Science direct.